van der Pijl R, Nusayr E, Strom J, Slater R, Gohlke J, Hourani Z
Circ Heart Fail. 2025; :e012083.
PMID: 39932400
PMC: 11905908.
DOI: 10.1161/CIRCHEARTFAILURE.124.012083.
Morotti I, Caremani M, Marcello M, Pertici I, Squarci C, Bianco P
Proc Natl Acad Sci U S A. 2024; 121(50):e2410893121.
PMID: 39630866
PMC: 11648670.
DOI: 10.1073/pnas.2410893121.
Vahle B, Heilmann L, Schauer A, Augstein A, Prieto Jarabo M, Barthel P
Int J Mol Sci. 2024; 25(12).
PMID: 38928324
PMC: 11203682.
DOI: 10.3390/ijms25126618.
Usui Y, Hanashima A, Hashimoto K, Kimoto M, Ohira M, Mohri S
Physiol Rep. 2024; 12(8):e16013.
PMID: 38644486
PMC: 11033294.
DOI: 10.14814/phy2.16013.
Ghaffari Jolfayi A, Kohansal E, Ghasemi S, Naderi N, Hesami M, MozafaryBazargany M
Sci Rep. 2024; 14(1):5313.
PMID: 38438525
PMC: 10912352.
DOI: 10.1038/s41598-024-56154-7.
Structural evidence for elastic tethers connecting separating chromosomes in crane-fly spermatocytes.
Forer A, Otsuka S
Life Sci Alliance. 2023; 6(11).
PMID: 37591724
PMC: 10435969.
DOI: 10.26508/lsa.202302303.
Eccentric muscle contractions: from single muscle fibre to whole muscle mechanics.
Tomalka A
Pflugers Arch. 2023; 475(4):421-435.
PMID: 36790515
PMC: 10011336.
DOI: 10.1007/s00424-023-02794-z.
The lack of Troponin I Ser-23/24 phosphorylation is detrimental to in vivo cardiac function and exacerbates cardiac disease.
Salhi H, Shettigar V, Salyer L, Sturgill S, Brundage E, Robinett J
J Mol Cell Cardiol. 2023; 176:84-96.
PMID: 36724829
PMC: 10074981.
DOI: 10.1016/j.yjmcc.2023.01.010.
Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF).
Valero-Munoz M, Saw E, Hekman R, Blum B, Hourani Z, Granzier H
Front Cardiovasc Med. 2022; 9:966968.
PMID: 36093146
PMC: 9452734.
DOI: 10.3389/fcvm.2022.966968.
Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations.
Maryniak A, Maisuradze N, Ahmed R, Biskupski P, Jayaraj J, Budzikowski A
Cardiol J. 2022; 29(4):670-679.
PMID: 35762077
PMC: 9273251.
DOI: 10.5603/CJ.a2022.0051.
The harder the climb the better the view: The impact of substrate stiffness on cardiomyocyte fate.
Querceto S, Santoro R, Gowran A, Grandinetti B, Pompilio G, Regnier M
J Mol Cell Cardiol. 2022; 166:36-49.
PMID: 35139328
PMC: 11270945.
DOI: 10.1016/j.yjmcc.2022.02.001.
The titin N2B and N2A regions: biomechanical and metabolic signaling hubs in cross-striated muscles.
Van der Pijl R, Domenighetti A, Sheikh F, Ehler E, Ottenheijm C, Lange S
Biophys Rev. 2021; 13(5):653-677.
PMID: 34745373
PMC: 8553726.
DOI: 10.1007/s12551-021-00836-3.
The ryanodine receptor stabilizer S107 ameliorates contractility of adult Rbm20 knockout rat cardiomyocytes.
Guo W, Zhu C, Yin Z, Zhang Y, Wang C, Walk A
Physiol Rep. 2021; 9(17):e15011.
PMID: 34523260
PMC: 8440945.
DOI: 10.14814/phy2.15011.
Blocking Protein Phosphatase 1 [PP1] Prevents Loss of Tether Elasticity in Anaphase Crane-Fly Spermatocytes.
Forer A, Adil A, Berns M
Front Mol Biosci. 2021; 8:636746.
PMID: 34169091
PMC: 8218814.
DOI: 10.3389/fmolb.2021.636746.
Muscle ankyrin repeat protein 1 (MARP1) locks titin to the sarcomeric thin filament and is a passive force regulator.
Van der Pijl R, Van Den Berg M, van de Locht M, Shen S, Bogaards S, Conijn S
J Gen Physiol. 2021; 153(7).
PMID: 34152365
PMC: 8222902.
DOI: 10.1085/jgp.202112925.
Novel insights into sarcomere regulatory systems control of cardiac thin filament activation.
Solis C, Solaro R
J Gen Physiol. 2021; 153(7).
PMID: 33740037
PMC: 7988513.
DOI: 10.1085/jgp.202012777.
Response by Methawasin and Granzier to Letter Regarding Article, "Phosphodiesterase 9a Inhibition in Mouse Models of Diastolic Dysfunction".
Methawasin M, Granzier H
Circ Heart Fail. 2021; 14(1):e007755.
PMID: 33464951
PMC: 7839309.
DOI: 10.1161/CIRCHEARTFAILURE.120.007755.
Multiscale Modeling of Cardiovascular Function Predicts That the End-Systolic Pressure Volume Relationship Can Be Targeted via Multiple Therapeutic Strategies.
Campbell K, Chrisman B, Campbell S
Front Physiol. 2020; 11:1043.
PMID: 32973561
PMC: 7466769.
DOI: 10.3389/fphys.2020.01043.
Modifications of Titin Contribute to the Progression of Cardiomyopathy and Represent a Therapeutic Target for Treatment of Heart Failure.
Tharp C, Mestroni L, Taylor M
J Clin Med. 2020; 9(9).
PMID: 32859027
PMC: 7564493.
DOI: 10.3390/jcm9092770.
Deleting Titin's C-Terminal PEVK Exons Increases Passive Stiffness, Alters Splicing, and Induces Cross-Sectional and Longitudinal Hypertrophy in Skeletal Muscle.
Van der Pijl R, Hudson B, Granzier-Nakajima T, Li F, Knottnerus A, Smith J
Front Physiol. 2020; 11:494.
PMID: 32547410
PMC: 7274174.
DOI: 10.3389/fphys.2020.00494.